The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Selumetinib in Children with Inoperable Plexiform Neurofibromas
Open accessAbstract
BACKGROUND: No approved therapies exist for inoperable plexiform neurofibromas in patients with neurofibromatosis type 1. METHODS: We conducted an open-label, phase 2 trial of selumetinib to determine the objective response rate among patients with plexiform neurofibromas and to assess clinical benefit. Children with neurofibromatosis type 1 and symptomatic inoperable plexiform neurofibromas received oral selumetinib twice daily at a dose of 25 mg per square meter of body-surface area on a continuous dosing schedule (28-day cycles). Volumetric magnetic resonance imaging and clinical outcome assessments (pain, quality of life, disfigurement, and function) were performed at least every four cycles. Children rated tumor pain intensity on a scale from 0 (no pain) to 10 (worst pain imaginable). RESULTS: A total of 50 children (median age, 10.2 years; range, 3.5 to 17.4) were enrolled from August 2015 through August 2016. The most frequent neurofibroma-related symptoms were disfigurement (44 patients), motor dysfunction (33), and pain (26). A total of 35 patients (70%) had a confirmed partial response as of March 29, 2019, and 28 of these patients had a durable response (lasting ≥1 year). After 1 year of treatment, the mean decrease in child-reported tumor pain-intensity scores was 2 points, considered a clinically meaningful improvement. In addition, clinically meaningful improvements were seen in child-reported and parent-reported interference of pain in daily functioning (38% and 50%, respectively) and overall health-related quality of life (48% and 58%, respectively) as well as in functional outcomes of strength (56% of patients) and range of motion (38% of patients). Five patients discontinued treatment because of toxic effects possibly related to selumetinib, and 6 patients had disease progression. The most frequent toxic effects were nausea, vomiting, or diarrhea; an asymptomatic increase in the creatine phosphokinase level; acneiform rash; and paronychia. CONCLUSIONS: In this phase 2 trial, most children with neurofibromatosis type 1 and inoperable plexiform neurofibromas had durable tumor shrinkage and clinical benefit from selumetinib. (Funded by the Intramural Research Program of the National Institutes of Health and others; ClinicalTrials.gov number, NCT01362803.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regularization Paths for Generalized Linear Models via Coordinate Descent
Friedman, J., Hastie, T., & Tibshirani, R. (2010) · Journal of Statistical Software · doi:10.18637/jss.v033.i01 · Cited by 19,927
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
(1976) · Medical Entomology and Zoology · Cited by 8,899
Varni, J. W., Seid, M., & Kurtin, P. S. (2001) · Medical Care · doi:10.1097/00005650-200108000-00006 · Cited by 5,131
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003) · Medical Care · doi:10.1097/01.mlr.0000062554.74615.4c · Cited by 4,700
Core outcome domains for chronic pain clinical trials: IMMPACT recommendations
Turk, D. C., Dworkin, R. H., Allen, R. R., Bellamy, N., Brandenburg, N., Carr, D. B., Cleeland, C., Dionne, R., Farrar, J. T., Galer, B. S., et al. (2003) · Pain · doi:10.1016/j.pain.2003.08.001 · Cited by 3,510
The PedsQL™* 4.0 as a Pediatric Population Health Measure: Feasibility, Reliability, and Validity
Varni, J. W., Burwinkle, T. M., Seid, M., & Skarr, D. (2003) · Ambulatory Pediatrics · doi:10.1367/1539-4409(2003)003<0329:tpaapp>2.0.co;2 · Cited by 2,324
Studies with pain rating scales.
Downie, W. W., Leatham, P. A., Rhind, V. M., Wright, V, Branco, J. A., & Anderson, J. A. (1978) · Annals of the Rheumatic Diseases · doi:10.1136/ard.37.4.378 · Cited by 1,978
Salaffi, F., Stancati, A., Silvestri, C. A., Ciapetti, A., & Grassi, W. (2004) · European Journal of Pain · doi:10.1016/j.ejpain.2003.09.004 · Cited by 1,724
Oostveen, E., MacLeod, D., Lorino, H., Farré, R., Hantos, Z., Desager, K., & Marchal, F. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00089403 · Cited by 1,302
Defining the clinically important difference in pain outcome measures
Farrar, J. T., Portenoy, R. K., Berlin, J. A., Kinman, J. L., & Strom, B. L. (2000) · Pain · doi:10.1016/s0304-3959(00)00339-0 · Cited by 1,071
Neurofibromatosis Type 1 Revisited
Williams, V. C., Lucas, J., Babcock, M. A., Gutmann, D. H., Korf, B., & Maria, B. L. (2009) · Pediatrics · doi:10.1542/peds.2007-3204 · Cited by 695
Activity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas
Dombi, E., Baldwin, A., Marcus, L. J., Fisher, M. J., Weiss, B., Kim, A., Whitcomb, P., Martin, S., Aschbacher-Smith, L. E., Rizvi, T. A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1605943 · Cited by 682
Self-citationNormal range of motion of joints in male subjects.
Boone, D. C., & Azen, S. P. (1979) · The Journal of Bone & Joint Surgery · doi:10.2106/00004623-197961050-00017 · Cited by 674
Six-Minute Walk Test in Children and Adolescents
Geiger, R., Strasak, A., Treml, B., Gasser, K., Kleinsasser, A., Fischer, V., Geiger, H., Loeckinger, A., & Stein, J. I. (2007) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2006.12.052 · Cited by 653
von Baeyer, C. L., Spagrud, L. J., McCormick, J. C., Choo, E., Neville, K., & Connelly, M. A. (2009) · Pain · doi:10.1016/j.pain.2009.03.002 · Cited by 575
Clinimetrics corner: a closer look at the minimal clinically important difference (MCID)
Wright, A., Hannon, J., Hegedus, E. J., & Kavchak, A. E. (2012) · Journal of Manual & Manipulative Therapy · doi:10.1179/2042618612y.0000000001 · Cited by 539
Fangusaro, J., Onar-Thomas, A., Young Poussaint, T., Wu, S., Ligon, A. H., Lindeman, N., Banerjee, A., Packer, R. J., Kilburn, L. B., Goldman, S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30277-3 · Cited by 507
Self-citationSOUCIE, J. M., WANG, C., FORSYTH, A., FUNK, S., DENNY, M., ROACH, K. E., BOONE, D., & THE HEMOPHILIA TREATMENT CENTER NETWORK (2011) · Haemophilia · doi:10.1111/j.1365-2516.2010.02399.x · Cited by 466
Wicksell, R. K., Melin, L., Lekander, M., & Olsson, G. L. (2009) · Pain · doi:10.1016/j.pain.2008.11.006 · Cited by 393
Korf, B. R. (1999) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19990326)89:1<31::aid-ajmg7>3.0.co;2-w · Cited by 390
Varni, J. W., Burwinkle, T. M., & Seid, M. (2005) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.5.6.705 · Cited by 335
MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors
Jessen, W. J., Miller, S. J., Jousma, E., Wu, J., Rizvi, T. A., Brundage, M. E., Eaves, D., Widemann, B., Kim, M.-O., Dombi, E., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci60578 · Cited by 334
Self-citationBanerjee, A., Jakacki, R. I., Onar-Thomas, A., Wu, S., Nicolaides, T., Young Poussaint, T., Fangusaro, J., Phillips, J., Perry, A., Turner, D., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now282 · Cited by 319
Self-citationDeWalt, D. A., Gross, H. E., Gipson, D. S., Selewski, D. T., DeWitt, E. M., Dampier, C. D., Hinds, P. S., Huang, I.-C., Thissen, D., & Varni, J. W. (2015) · Quality of Life Research · doi:10.1007/s11136-015-0953-3 · Cited by 264
Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1
Mautner, V.-F., Asuagbor, F. A., Dombi, E., Fünsterer, C., Kluwe, L., Wenzel, R., Widemann, B. C., & Friedman, J. M. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-011 · Cited by 260
Self-citationApproaches for estimating minimal clinically important differences in systemic lupus erythematosus
Rai, S. K., Yazdany, J., Fortin, P. R., & Aviña-Zubieta, J. A. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0658-6 · Cited by 251
NF1 plexiform neurofibroma growth rate by volumetric MRI: Relationship to age and body weight
Dombi, E., Solomon, J., Gillespie, A. J., Fox, E., Balis, F. M., Patronas, N., Korf, B. R., Babovic-Vuksanovic, D., Packer, R. J., Belasco, J., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000250332.89420.e6 · Cited by 202
Self-citationDeWitt, E. M., Stucky, B. D., Thissen, D., Irwin, D. E., Langer, M., Varni, J. W., Lai, J.-S., Yeatts, K. B., & DeWalt, D. A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.10.012 · Cited by 189
Visual acuity as an outcome measure in clinical trials of retinal diseases
Beck, R. W., Maguire, M. G., Bressler, N. M., Glassman, A. R., Lindblad, A. S., & Ferris, F. L. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.06.047 · Cited by 188
Normal global motion of the cervical spine:
Feipel, V., Rondelet, B., Le Pallec, J.-P., & Rooze, M. (1999) · Clinical Biomechanics · doi:10.1016/s0268-0033(98)90098-5 · Cited by 159
Nguyen, R., Kluwe, L., Fuensterer, C., Kentsch, M., Friedrich, R. E., & Mautner, V.-F. (2011) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2011.04.008 · Cited by 159
Weiss, B., Widemann, B. C., Wolters, P. L., Dombi, E., Vinks, A. A. T. M. M., Cantor, A. B., Perentesis, J. P., Schorry, E. K., Ullrich, N. J., Gutmann, D. H., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou235 · Cited by 156
Self-citationRecommendations for imaging tumor response in neurofibromatosis clinical trials
Dombi, E., Ardern‐Holmes, S. L., Babovic‐Vuksanovic, D., Barker, F. G., Connor, S. E. J., Evans, D. G., Fisher, M. J., Goutagny, S., Harris, G. J., Jaramillo, D., et al. (2013) · Neurology · doi:10.1212/01.wnl.0000435744.57038.af · Cited by 153
Self-citationWeiss, B., Wolters, P. L., Plotkin, S. R., Widemann, B. C., Tonsgard, J. H., Blakeley, J. O., Allen, J. C., Schorry, E. K., Korf, B. R., Robison, N. J., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02220 · Cited by 148
Self-citationHilliard, M. E., Lawrence, J. M., Modi, A. C., Anderson, A., Crume, T., Dolan, L. M., Merchant, A. T., Yi‐Frazier, J. P., Hood, K. K., & for the SEARCH for Diabetes in Youth Study Group (2013) · Diabetes Care · doi:10.2337/dc12-1708 · Cited by 131
Widemann, B. C., Dombi, E., Gillespie, A., Wolters, P. L., Belasco, J. B., Goldman, S., Korf, B. R., Solomon, J. M., Martin, S. C., Salzer, W. L., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou004 · Cited by 124
Self-citationThe Neurofibromatosis Type 1 Gene
Viskochil, D. H., White, R. L., & Cawthon, R. (1993) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.16.030193.001151 · Cited by 116
Gross, A. M., Singh, G., Akshintala, S., Baldwin, A. M., Dombi, E., Ukwuani, S., Goodwin, A., Liewehr, D. J., Steinberg, S. M., & Widemann, B. C. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy067 · Cited by 116
Self-citationWidemann, B. C., Babovic‐Vuksanovic, D., Dombi, E., Wolters, P. L., Goldman, S., Martin, S. C., Goodwin, A., Goodspeed, W. J., Kieran, M. W., Cohen, B. H., et al. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25041 · Cited by 103
Self-citationSubretinal Fluid Associated with MEK Inhibitor Use in the Treatment of Systemic Cancer
Weber, M. L., Liang, M. C., Flaherty, K. T., & Heier, J. S. (2016) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2016.0090 · Cited by 86
Optimizing biologically targeted clinical trials for neurofibromatosis
Gutmann, D. H., Blakeley, J. O., Korf, B. R., & Packer, R. J. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.772979 · Cited by 85
Self-citationJakacki, R. I., Dombi, E., Steinberg, S. M., Goldman, S., Kieran, M. W., Ullrich, N. J., Pollack, I. F., Goodwin, A., Manley, P. E., Fangusaro, J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now158 · Cited by 78
Self-citationMcCowage, G. B., Mueller, S., Pratilas, C. A., Hargrave, D. R., Moertel, C. L., Whitlock, J. A., Fox, E., Hingorani, P., Russo, M. W., Dasgupta, K., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.10504 · Cited by 62
Martin, S., Nelson Schmitt, S., Wolters, P. L., Abel, B., Toledo-Tamula, M. A., Baldwin, A., Wicksell, R. K., Merchant, M., & Widemann, B. (2015) · Pain Medicine · doi:10.1111/pme.12620 · Cited by 48
Self-citationTrametinib Induces Neurofibroma Shrinkage and Enables Surgery
Vaassen, P., Dürr, N. R., Röhrig, A., Willing, R., & Rosenbaum, T. (2019) · Neuropediatrics · doi:10.1055/s-0039-1691830 · Cited by 47
Clinically meaningful measurement of pain in children with sickle cell disease
Myrvik, M. P., Brandow, A. M., Drendel, A. L., Yan, K., Hoffmann, R. G., & Panepinto, J. A. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24624 · Cited by 42
Abdel-Rahman, O. M., Elhalawani, H. M., & Ahmed, H. (2015) · Journal of Global Oncology · doi:10.1200/jgo.2015.000802 · Cited by 39
Holmström, L., Kemani, M. K., Kanstrup, M., & Wicksell, R. K. (2015) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0000000000000191 · Cited by 37
Separation of outer retinal layers secondary to selumetinib
Avery, R. A., Trimboli−Heidler, C., & Kilburn, L. B. (2016) · Journal of American Association for Pediatric Ophthalmology and Strabismus · doi:10.1016/j.jaapos.2016.01.012 · Cited by 30
Pradhan, K. R., Mund, J. A., Johnson, C. S., Vik, T. A., Ingram, D. A., & Case, J. (2011) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.20602 · Cited by 24
Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1
Plotkin, S. R., Davis, S. D., Robertson, K. A., Akshintala, S., Allen, J. L., Fisher, M. J., Blakeley, J. O., Widemann, B. C., Ferner, R. E., Marcus, C. L., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002933 · Cited by 19
Self-citationWeiss, B., Plotkin, S. R., Widemann, B. C., Tonsgard, J. H., Blakeley, J. O., Allen, J. C., Schorry, E. K., Korf, B. R., Rosser, T. L., Goldman, S., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy059.514 · Cited by 18
Self-citation
Cited by
Gronchi, A., Miah, A. B., Dei Tos, A. P., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J. Y., Bolle, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.07.006 · Cited by 1,115
Legius, E., Messiaen, L., Wolkenstein, P., Pancza, P., Avery, R. A., Berman, Y., Blakeley, J., Babovic-Vuksanovic, D., Cunha, K. S., Ferner, R., et al. (2021) · Genetics in Medicine · doi:10.1038/s41436-021-01170-5 · Cited by 825
Self-citationTyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
Huang, L., Jiang, S., & Shi, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00977-0 · Cited by 456
MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma
Moon, H., & Ro, S. W. (2021) · Cancers · doi:10.3390/cancers13123026 · Cited by 326
Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
Ayala-Aguilera, C. C., Valero, T., Lorente-Macías, Á., Baillache, D. J., Croke, S., & Unciti-Broceta, A. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00963 · Cited by 265
Metadata
- Authors
- Gross, A. M., Wolters, P. L., Dombi, E., Baldwin, A., Whitcomb, P., Fisher, M. J., Weiss, B., Kim, A., Bornhorst, M., Shah, A. C., Martin, S., Roderick, M. C., Pichard, D. C., Carbonell, A., Paul, S. M., Therrien, J., Kapustina, O., Heisey, K., Clapp, D. W., Zhang, C., Peer, C. J., Figg, W. D., Smith, M., Glod, J., Blakeley, J. O., Steinberg, S. M., Venzon, D. J., Doyle, L. A., & Widemann, B. C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-04-09
- Volume
- 382
- Issue
- 15
- Pages
- 1430-1442
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3010907970
- Cited by
- 726
- References
- 53
- FWCI
- 33.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.